New Mexico Educational Retirement Board Buys 8,250 Shares of Charles River Laboratories International, Inc. $CRL

New Mexico Educational Retirement Board lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL – Free Report) by 330.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 10,750 shares of the medical research company’s stock after purchasing an additional 8,250 shares during the quarter. New Mexico Educational Retirement Board’s holdings in Charles River Laboratories International were worth $3,171,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in CRL. Dimensional Fund Advisors LP increased its stake in shares of Charles River Laboratories International by 14.6% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,652,484 shares of the medical research company’s stock worth $285,001,000 after acquiring an additional 210,260 shares during the last quarter. Bank of America Corp DE boosted its position in shares of Charles River Laboratories International by 5.0% during the 1st quarter. Bank of America Corp DE now owns 1,135,027 shares of the medical research company’s stock valued at $195,792,000 after acquiring an additional 54,500 shares during the last quarter. Amundi grew its holdings in shares of Charles River Laboratories International by 175.2% in the first quarter. Amundi now owns 773,315 shares of the medical research company’s stock valued at $133,397,000 after purchasing an additional 492,301 shares during the period. Van Berkom & Associates Inc. grew its holdings in shares of Charles River Laboratories International by 11.2% in the first quarter. Van Berkom & Associates Inc. now owns 501,152 shares of the medical research company’s stock valued at $86,449,000 after purchasing an additional 50,462 shares during the period. Finally, Assenagon Asset Management S.A. increased its position in Charles River Laboratories International by 230.9% during the third quarter. Assenagon Asset Management S.A. now owns 204,537 shares of the medical research company’s stock worth $59,044,000 after purchasing an additional 142,716 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Insider Transactions at Charles River Laboratories International

In other news, Director James C. Foster sold 33,561 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The stock was sold at an average price of $300.00, for a total value of $10,068,300.00. Following the completion of the sale, the director directly owned 31,596 shares of the company’s stock, valued at $9,478,800. This trade represents a 51.51% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Shannon Parisotto sold 2,156 shares of the company’s stock in a transaction dated Wednesday, October 21st. The stock was sold at an average price of $344.41, for a total transaction of $742,547.96. Following the transaction, the executive vice president owned 4,807 shares in the company, valued at $1,655,578.87. The trade was a 30.96% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 63,352 shares of company stock worth $20,291,281 over the last ninety days. 1.30% of the stock is currently owned by company insiders.

Charles River Laboratories International Stock Down 0.9%

Charles River Laboratories International stock opened at $342.81 on Thursday. The stock’s fifty day simple moving average is $309.32 and its 200-day simple moving average is $227.05. The company has a current ratio of 1.41, a quick ratio of 1.12 and a debt-to-equity ratio of 0.76. The firm has a market capitalization of $16.43 billion, a P/E ratio of 376.71, a P/E/G ratio of 3.13 and a beta of 1.36. Charles River Laboratories International, Inc. has a twelve month low of $146.20 and a twelve month high of $379.63.

Charles River Laboratories International (NYSE:CRL – Get Free Report) last released its quarterly earnings data on Wednesday, November 4th. The medical research company reported $3.09 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.97 by $0.12. Charles River Laboratories International had a return on equity of 16.95% and a net margin of 1.01%. The business had revenue of $982.73 million during the quarter, compared to analysts’ expectations of $960.36 million. During the same period in the prior year, the firm posted $2.43 EPS. The business’s quarterly revenue was down 2.2% compared to the same quarter last year. As a group, equities analysts expect that Charles River Laboratories International, Inc. will post 11.45 earnings per share for the current fiscal year.

Analyst Ratings Changes

CRL has been the topic of a number of analyst reports. Mizuho lifted their target price on shares of Charles River Laboratories International from $264.00 to $295.00 and gave the stock a “neutral” rating in a research note on Friday, September 25th. Zacks Research cut shares of Charles River Laboratories International from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 2nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Charles River Laboratories International in a report on Monday, September 28th. Morgan Stanley increased their price target on Charles River Laboratories International from $300.00 to $340.00 and gave the stock an “overweight” rating in a report on Monday, October 12th. Finally, Barclays raised their price objective on Charles River Laboratories International from $330.00 to $375.00 and gave the stock an “overweight” rating in a research report on Thursday, November 5th. Thirteen investment analysts have rated the stock with a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $308.17.

Read Our Latest Analysis on CRL

Charles River Laboratories International Profile

(Free Report)

Charles River Laboratories International is a contract research organization that supports pharmaceutical and biotechnology companies, as well as academic and government researchers, in developing medicines and advancing scientific research. Its services span the drug development process, from early discovery and preclinical research to manufacturing support. The company’s offerings include research models and related services, drug discovery and safety assessment, and manufacturing solutions. These may include laboratory animal models, laboratory testing, bioanalysis, and support for the production of products used in the development of pharmaceuticals and biologics.

Featured Articles

Institutional Ownership by Quarter for Charles River Laboratories International (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories International and related companies with MarketBeat.com's FREE daily email newsletter.